{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:27:44Z","timestamp":1760747264680,"version":"build-2065373602"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"crossref","award":["197837"],"award-info":[{"award-number":["197837"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery is a potentially curative treatment for patients with peritoneal metastases. Currently, there is no standardized protocol for performing HIPEC and there is large variation in the key parameters. In vivo models can be a valuable tool to better understand the impact of these parameters and how to improve this treatment strategy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Peritoneal tumors were established in immunodeficient mice by intraperitoneal injection of the high-grade serous human ovarian cancer cell line B76. Thirty-minute perfusion with cisplatin or mitomycin C at 37 or 41\u00a0\u00b0C was performed 4\u00a0days later. Treatment efficacy was assessed by measuring bioluminescence and overall survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We successfully established a closed peritoneal chemotherapy perfusion model in mice bearing peritoneal metastases. Perfusion with cisplatin and mitomycin C significantly inhibited tumor growth and increased overall survival by 38\u201348%. The addition of hyperthermia did not improve survival, although a clear synergistic effect with hyperthermia was observed in vitro for both drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The results suggest that intraperitoneal perfusion of cisplatin and mitomycin C can be a valuable adjuvant to cytoreductive surgery, while the addition of moderate hyperthermia did not improve efficacy. Additional studies investigating long-term outcome are necessary to determine the impact of hyperthermia as a component of the HIPEC procedure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-18025-x","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:12:00Z","timestamp":1754914320000},"page":"9333-9340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intraperitoneal Perfusion with Cisplatin or Mitomycin C Improves Survival in Mice Bearing Peritoneal Metastases from Ovarian Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Yvonne","family":"Andersson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil","family":"L\u00f8vstakken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodor Malmer","family":"Herud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein","family":"Waagene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjersti","family":"Flatmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0697-9750","authenticated-orcid":false,"given":"Karianne Giller","family":"Fleten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"7","key":"18025_CR1","first-page":"424","volume":"99","author":"J Sehouli","year":"2009","unstructured":"Sehouli J, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99(7):424\u20137.","journal-title":"J Surg Oncol"},{"issue":"4","key":"18025_CR2","first-page":"446","volume":"32","author":"N van den Tempel","year":"2016","unstructured":"van den Tempel N, Horsman MR, Kanaar R. Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms. Int J Hyperthermia. 2016;32(4):446\u201354.","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"18025_CR3","first-page":"230","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340.","journal-title":"N Engl J Med"},{"issue":"12","key":"18025_CR4","first-page":"1551","volume":"25","author":"JM Classe","year":"2024","unstructured":"Classe JM, et al. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2024;25(12):1551\u201362.","journal-title":"Lancet Oncol"},{"issue":"5","key":"18025_CR5","first-page":"1570","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570\u20135.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"18025_CR6","first-page":"2426","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426\u201332.","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"18025_CR7","first-page":"3756","volume":"116","author":"J Franko","year":"2010","unstructured":"Franko J, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756\u201362.","journal-title":"Cancer"},{"issue":"Suppl 1","key":"18025_CR8","first-page":"S129","volume":"12","author":"PH Sugarbaker","year":"2021","unstructured":"Sugarbaker PH, Van der Speeten K. The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens. J Gastrointest Oncol. 2021;12(Suppl 1):S129-s130.","journal-title":"J Gastrointest Oncol"},{"issue":"23","key":"18025_CR9","first-page":"2594","volume":"39","author":"O Zivanovic","year":"2021","unstructured":"Zivanovic O, et al. Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study. J Clin Oncol. 2021;39(23):2594\u2013604.","journal-title":"J Clin Oncol"},{"issue":"5","key":"18025_CR10","first-page":"374","volume":"157","author":"MC Lim","year":"2022","unstructured":"Lim MC, et al. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374\u201383.","journal-title":"JAMA Surg"},{"issue":"1","key":"18025_CR11","first-page":"78","volume":"11","author":"R Helderman","year":"2019","unstructured":"Helderman R, et al. Variation in clinical application of hyperthermic intraperitoneal chemotherapy: a review. Cancers. 2019;11(1):78.","journal-title":"Cancers"},{"issue":"1","key":"18025_CR12","first-page":"51","volume":"34","author":"KG Fleten","year":"2017","unstructured":"Fleten KG, et al. Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases. Clin Exp Metastasis. 2017;34(1):51\u201362.","journal-title":"Clin Exp Metastasis"},{"key":"18025_CR13","first-page":"81","volume":"10","author":"R Loew","year":"2010","unstructured":"Loew R, et al. Improved Tet-responsive promoters with minimized background expression. BMC Biotechnol. 2010;10:81.","journal-title":"BMC Biotechnol"},{"issue":"8","key":"18025_CR14","first-page":"1775","volume":"9","author":"R Helderman","year":"2020","unstructured":"Helderman R, et al. The temperature-dependent effectiveness of platinum-based drugs mitomycin-C and 5-FU during hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer cell lines. Cells. 2020;9(8):1775.","journal-title":"Cells"},{"key":"18025_CR15","volume":"48","author":"A Hyldbakk","year":"2023","unstructured":"Hyldbakk A, et al. Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models. Nanomedicine. 2023;48:102656.","journal-title":"Nanomedicine"},{"issue":"2","key":"18025_CR16","first-page":"94","volume":"1","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. J Pharmacol Pharmacother. 2010;1(2):94\u20139.","journal-title":"J Pharmacol Pharmacother"},{"issue":"3","key":"18025_CR17","first-page":"319","volume":"49","author":"MH Ullman-Culler\u00e9","year":"1999","unstructured":"Ullman-Culler\u00e9 MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci. 1999;49(3):319\u201323.","journal-title":"Lab Anim Sci"},{"key":"18025_CR18","first-page":"310","volume":"233","author":"E McCabe-Lankford","year":"2019","unstructured":"McCabe-Lankford E, et al. Murine models of intraperitoneal perfusion for disseminated colorectal cancer. J Surg Res. 2019;233:310\u201322.","journal-title":"J Surg Res"},{"issue":"1","key":"18025_CR19","first-page":"95","volume":"22","author":"Q Wang","year":"2023","unstructured":"Wang Q, et al. Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases. Mol Cancer. 2023;22(1):95.","journal-title":"Mol Cancer"},{"issue":"11","key":"18025_CR20","first-page":"2888","volume":"47","author":"VCJ van de Vlasakker","year":"2021","unstructured":"van de Vlasakker VCJ, et al. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2021;47(11):2888\u201392.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"18025_CR21","first-page":"400","volume":"45","author":"W Ceelen","year":"2019","unstructured":"Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road? Eur J Surg Oncol. 2019;45(3):400\u20132.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"18025_CR22","first-page":"2657","volume":"30","author":"R Geva","year":"2023","unstructured":"Geva R, et al. PD-1 blockade combined with heated intraperitoneal chemotherapy improves outcome in experimental peritoneal metastases from colonic origin in a murine model. Ann Surg Oncol. 2023;30(5):2657\u201363.","journal-title":"Ann Surg Oncol"},{"key":"18025_CR23","volume":"116","author":"N Nevo","year":"2023","unstructured":"Nevo N, et al. Immunological effects of heated intraperitoneal chemotherapy can be augmented by thymosin \u03b11. Int Immunopharmacol. 2023;116:109829.","journal-title":"Int Immunopharmacol"},{"key":"18025_CR24","volume":"111","author":"N Nevo","year":"2022","unstructured":"Nevo N, et al. Thymosin alpha 1 as an adjuvant to hyperthermic intraperitoneal chemotherapy in an experimental model of peritoneal metastases from colonic carcinoma. Int Immunopharmacol. 2022;111:109166.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"18025_CR25","first-page":"730","volume":"256","author":"K Lehmann","year":"2012","unstructured":"Lehmann K, et al. New insight into hyperthermic intraperitoneal chemotherapy: induction of oxidative stress dramatically enhanced tumor killing in in vitro and in vivo models. Ann Surg. 2012;256(5):730\u20137.","journal-title":"Ann Surg"},{"issue":"3","key":"18025_CR26","first-page":"123","volume":"8","author":"B Mano\u011flu","year":"2023","unstructured":"Mano\u011flu B, et al. Investigation of the effectiveness of hyperthermic intraperitoneal chemotherapy in experimental colorectal peritoneal metastasis model. Pleura Peritoneum. 2023;8(3):123\u201331.","journal-title":"Pleura Peritoneum"},{"key":"18025_CR27","first-page":"149","volume":"92","author":"C Qiu","year":"2017","unstructured":"Qiu C, et al. A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with Raltitrexed. Biomed Pharmacother. 2017;92:149\u201356.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"18025_CR28","first-page":"542","volume":"245","author":"Q Gong","year":"2020","unstructured":"Gong Q, et al. Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-\u03b1 and raltitrexed in mice with colorectal-peritoneal carcinomatosis. Exp Biol Med. 2020;245(6):542\u201351.","journal-title":"Exp Biol Med"},{"key":"18025_CR29","first-page":"256","volume":"131","author":"C Carlier","year":"2016","unstructured":"Carlier C, et al. Nanoscopic tumor tissue distribution of platinum after intraperitoneal administration in a xenograft model of ovarian cancer. J Pharm Biomed Anal. 2016;131:256\u201362.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"18025_CR30","first-page":"39","volume":"26","author":"L Graziosi","year":"2012","unstructured":"Graziosi L, et al. Gene expression changes induced by HIPEC in a murine model of gastric cancer. In Vivo. 2012;26(1):39\u201345.","journal-title":"In Vivo"},{"issue":"6","key":"18025_CR31","first-page":"511","volume":"36","author":"O S\u00f8rensen","year":"2019","unstructured":"S\u00f8rensen O, et al. Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei. Clin Exp Metastasis. 2019;36(6):511\u20138.","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"18025_CR32","first-page":"125","volume":"254","author":"YL Klaver","year":"2011","unstructured":"Klaver YL, et al. Hyperthermia and intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis: an experimental study. Ann Surg. 2011;254(1):125\u201330.","journal-title":"Ann Surg"},{"key":"18025_CR33","first-page":"1122755","volume":"13","author":"R Helderman","year":"2023","unstructured":"Helderman R, et al. Elevated temperatures and longer durations improve the efficacy of oxaliplatin- and mitomycin C-based hyperthermic intraperitoneal chemotherapy in a confirmed rat model for peritoneal metastasis of colorectal cancer origin. Front Oncol. 2023;13:1122755.","journal-title":"Front Oncol"},{"key":"18025_CR34","first-page":"88","volume":"2","author":"A Derrien","year":"2015","unstructured":"Derrien A, et al. Therapeutic efficacy of Alpha-RIT using a (213)Bi-Anti-hCD138 antibody in a mouse model of ovarian peritoneal carcinomatosis. Front Med. 2015;2:88.","journal-title":"Front Med"},{"key":"18025_CR35","first-page":"262","volume":"253","author":"LF Liesenfeld","year":"2020","unstructured":"Liesenfeld LF, et al. Impact of perfusate concentration on hyperthermic intraperitoneal chemotherapy efficacy and toxicity in a rodent model. J Surg Res. 2020;253:262\u201371.","journal-title":"J Surg Res"},{"issue":"4","key":"18025_CR36","first-page":"441","volume":"20","author":"M Kudo","year":"2004","unstructured":"Kudo M, et al. Closed continuous hyperthermic peritoneal perfusion model in mice with peritoneal dissemination of colon 26. Int J Hyperthermia. 2004;20(4):441\u201350.","journal-title":"Int J Hyperthermia"},{"key":"18025_CR37","first-page":"9","volume":"4","author":"CS Muenyi","year":"2011","unstructured":"Muenyi CS, et al. Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC). J Ovarian Res. 2011;4:9.","journal-title":"J Ovarian Res."},{"issue":"11","key":"18025_CR38","volume":"68","author":"BR Wagner","year":"2021","unstructured":"Wagner BR, et al. Establishment of a new valid animal model for the evaluation of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric rhabdomyosarcoma. Pediatric Blood Cancer. 2021;68(11):e29202.","journal-title":"Pediatric Blood Cancer."},{"issue":"12","key":"18025_CR39","first-page":"3516","volume":"12","author":"DR L\u00f6ke","year":"2020","unstructured":"L\u00f6ke DR, et al. A four-inflow construction to ensure thermal stability and uniformity during hyperthermic intraperitoneal chemotherapy (HIPEC) in rats. Cancers. 2020;12(12):3516.","journal-title":"Cancers"},{"issue":"10","key":"18025_CR40","first-page":"1109","volume":"24","author":"SL Aronson","year":"2023","unstructured":"Aronson SL, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 2023;24(10):1109\u201318.","journal-title":"Lancet Oncol."},{"issue":"1","key":"18025_CR41","volume":"33","author":"R Farrell","year":"2022","unstructured":"Farrell R, et al. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901\/2020). J Gynecol Oncol. 2022;33(1):e1.","journal-title":"J Gynecol Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18025-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:41:21Z","timestamp":1760715681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18025-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["18025"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18025-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yvonne Andersson, Emil L\u00f8vstakken, Theodor Malmer Herud, Stein Waagene, Kjersti Flatmark, and Karianne Giller Fleten have no disclosures to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}